Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: A study in Swedes

Pharmacogenetics and Genomics

Volumn 20, Issue 2, 2010, Pages 94-103

  Fava, Cristiano ^a,b   Montagnana, Martina ^a,b   Danese, Elisa ^a,b   Almgren, Peter ^a   Hedblad, Bo ^a   Engström, Gunnar ^a   Berglund, Göran ^a   Minuz, Pietro ^b   Melander, Olle ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Association; Functional; Hypertension; Ischemic stroke; Myocardial infarction; Polymorphism; Soluble epoxide hydrolase

Indexed keywords

ALANINE; C REACTIVE PROTEIN; CHOLESTEROL; CYSTEINE; EPOXIDE HYDROLASE; GLYCINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SOLUBLE EPOXIDE HYDROLASE; THREONINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GENE INTERACTION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MISSENSE MUTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AMINO ACID SUBSTITUTION; BLOOD PRESSURE; DEMOGRAPHY; ENDPOINT DETERMINATION; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; HYPERTENSION; INCIDENCE; ISCHEMIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX CHARACTERISTICS; STROKE; SWEDEN;

EID: 75649101239     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283349ec9     Document Type: Article

References (52)

1. Imig JD. Epoxygenase metabolites: epithelial and vascular actions. Mol Biotechnol 2000; 16:233-251.
2. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
3. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007; 292:C996-C1012.
4. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci 2007; 104:9018-9023.
5. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005; 45:759-765.
6. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002; 39:690-694.
7. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 2007; 47:87-98.
8. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 2007; 293:F342-F349.
9. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005; 46:975-981.
10. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15:1244-1253.
11. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006; 18:442-450.
12. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008; 40:529-537.
13. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-ylureido) dodecanoic acid (AUDA) reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005; 46:842-848.
14. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai H-J, Morisseau C, et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007; 27:1931-1940.
15. Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008; 51:567-573.
16. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000; 275:40504-40510.
17. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 2007; 282:2891-2898.
18. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels. Circulation 2003; 107:769-776.
19. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, et al. Altered release of cytochrome P450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008; 51:1-7.
20. Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 2004; 287:H2412-H2420.
21. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52:447-454.
22. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson BD, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 2004; 286:F720-F726.
23. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005; 14:2829-2837.
24. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 2008; 39:1593-1596.
25. Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, et al. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharmacogenet Genomics 2008; 18:45-51.
26. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006; 15:1640-1649.
27. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DRJ, Siscovick DS, Fornage M. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007; 190:26-34.
28. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003; 64:482-490.
29. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 2000; 275:28873-28881.
30. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 2004; 427:164-169.
31. Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005; 18:1276-1281.
32. Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 2004; 49:29-34.
33. Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S, Kim YS. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008; 40:1353-1356.
34. Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, et al. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 2008; 5:128-134.
35. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31:3568-3571.
36. Fairbrother WG, Yeh RF, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. Science 2002; 297: 1007-1013.
37. Sandelin A, Wasserman WW, Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 2004; 32:W249-W252.
38. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo diet and cancer study. Design and feasibility. J Intern Med 1993; 233:45-51.
39. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779-1786.
40. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41:207-210.
41. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects-a population-based study comparing three different definitions. Diabet Med 2007; 24:464-472.
42. Montagnana M, Fava C, Nilsson PM, Engström G, Hedblad B, Lippi G, et al. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban based sample of middle aged Swedes. Diabet Med 2008; 25:902-908.
43. Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engström G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke 2007; 38:2681-2685.
44. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14:143-149.
45. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
46. Fava C, Montagnana M, Almgrena P, Rosberg L, Lippi G, Hedblad B, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedish beyond its effect on blood pressure. Hypertension 2008; 52:373-380.
47. Koerner IP, Zhang W, Cheng J, Parker S, Hurn PD, Alkayed NJ. Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci 2008; 13:2833-2841.
48. Pinot F, Grant DF, Spearow JL, Parker AG, Hammock BD. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 1995; 50:501-508.
49. Fava C, Montagnana M, Almgren P, Rosberg L, Guidi GC, Berglund G, Melander O. Association between adducin-1 G460W variant and blood pressure in Swedes is dependent on interaction with BMI and sex. Am J Hypertens 2007; 20:981-989.
50. Sura P, Sura R, Enayetallah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 2008; 56:551-559.
51. Campbell H, Carothers AD, Rudan I, Hayward C, Biloglav Z, Barac L, et al. Effects of genome-wide heterozygosity on a range of biomedically relevant human quantitative traits. Hum Mol Genet 2007; 16:233-241.
52. Govindaraju DR, Larson MG, Yin X, Benjamin EJ, Rao MB, Vasan RS. Association between SNP heterozygosity and quantitative traits in the Framingham Heart Study. Ann Hum Genet 2009; 73:465-473.